Current Surgical

Current Surgical is a medical technology company developing a high-resolution thermal ablation platform designed to treat solid tumors with high precision. The company's technology utilizes "smart" needles equipped with ultrasound sensors that allow clinicians to visualize, monitor, and destroy cancerous tissue in real-time. By providing immediate feedback during the ablation process, the platform aims to improve surgical outcomes and reduce damage to healthy tissue. This approach expands the treatable patient population for various solid organ cancers, including those in the liver, kidney, and pancreas. The company is currently in the pre-clinical development stage, focusing on oncology applications. Current Surgical was part of the Y Combinator W21 cohort and has received backing from prominent venture capital firms.